Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Bitopertin

Generic Name: Bitopertin

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₀F_₇N_₃O_₄S

CAS Number: 845614-11-1

Unique Ingredient Identifier: Q8L6AN59YY

Overview

Bitopertin has been used in trials studying the treatment of Schizophrenia and Obsessive-Compulsive Disorder.

Background

Bitopertin has been used in trials studying the treatment of Schizophrenia and Obsessive-Compulsive Disorder.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers

Phase 1

Completed

Posted: 2012/03/05

Sponsor:Hoffmann-La Roche

ID:NCT01543529

A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838

Phase 1

Completed

Posted: 2012/01/18

Sponsor:Hoffmann-La Roche

ID:NCT01510899

A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers

Phase 1

Completed

Posted: 2011/12/19

Sponsor:Hoffmann-La Roche

ID:NCT01495104

A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

Phase 1

Completed

Posted: 2011/09/22

Sponsor:Hoffmann-La Roche

ID:NCT01438749

A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers

Phase 1

Completed

Posted: 2011/09/14

Sponsor:Hoffmann-La Roche

ID:NCT01433575

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Disc Medicine Advances Bitopertin NDA for Erythropoietic Protoporphyria as Pipeline Progress Continues

14 days ago

Disc Medicine has initiated the APOLLO confirmatory trial for bitopertin in erythropoietic protoporphyria (EPP) and remains on track to submit an NDA under accelerated approval pathway in the second half of 2025.

FDA Aligns with Gemini Therapeutics on APOLLO Trial Design for Bitopertin in Rare Porphyria Disorders

4 months ago

Gemini Therapeutics has successfully concluded a Type C meeting with the FDA, reaching agreement on the design of APOLLO confirmatory trial for bitopertin in EPP and XLP treatment.

Boehringer Ingelheim's Iclepertin Fails to Meet Endpoints in Phase III Schizophrenia Trials

4 months ago

Boehringer Ingelheim's iclepertin, a GlyT1 inhibitor, failed to demonstrate statistically significant benefits in improving cognitive function in schizophrenia patients.

Boehringer Ingelheim Expands Schizophrenia Pipeline with Sosei Heptares and Autifony Collaborations

4 months ago

Boehringer Ingelheim licenses GPR52 agonists from Sosei Heptares for €755m, targeting a range of schizophrenia symptoms including positive, negative, and cognitive dysfunction.

Disc Medicine Advances Hematology Pipeline with Bitopertin NDA Plans and Phase 2 Trials

4 months ago

Disc Medicine is preparing for an NDA submission for bitopertin in erythropoietic protoporphyria (EPP) following positive FDA feedback, potentially leading to accelerated approval.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy